Provide feedbackProvide feedback

« Back

AstraZeneca, MedImmune collaborate with Axerion on biologic approach for AD

Wednesday, May 02 2012 | Comments
Evidence Grade 0 What's This?
MedImmune LLC, the biologics unit of AstraZeneca Plc, entered into a research collaboration and sublicense agreement with Axerion Therapeutics Inc., a privately held biotechnology firm based in Connecticut, to develop and commercialize a biologic approach to the treatment of Alzheimer's disease (AD).

Under the terms of the agreement, Axerion granted AstraZeneca an exclusive sublicense to research, develop and commercialize a preclinical biologic in exchange for certain up-front and milestone payments, as well as research and development funding. Axerion is also eligible to receive royalties on product sales.

The companies will work together to develop a biologic approach that blocks the toxic effects of amyloid-beta in AD by targeting the binding of amyloid-beta oligomers to cellular prion proteins in the brain.

The agreement with Axerion is the first collaboration involving AstraZeneca's new neuroscience Innovative Medicines unit. This "virtual" unit consists of a team of scientists who conduct discovery and development activities externally through a network of partners in academia and industry.

Axerion was established to develop and commercialize therapeutics for neurological diseases and injuries, such as AD and chronic spinal cord injury, using intellectual property exclusively licensed from Yale University.

Print  |  E-mail

Comments

Be the first to write a comment for this article!

You must be logged in to post a comment.